Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

BACKGROUND: BRAF-mutant melanoma patients respond to BRAF inhibitors and MEK inhibitors (BRAFi/MEKi), but drug-tolerant cells persist, which may seed disease progression. Adaptive activation of receptor tyrosine kinases (RTKs) has been associated with melanoma cell drug tolerance following targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiago, Manoela, Capparelli, Claudia, Erkes, Dan A., Purwin, Timothy J., Heilman, Shea A., Berger, Adam C., Davies, Michael A., Aplin, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078299/
https://www.ncbi.nlm.nih.gov/pubmed/31932756
http://dx.doi.org/10.1038/s41416-019-0724-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078299/
https://www.ncbi.nlm.nih.gov/pubmed/31932756
http://dx.doi.org/10.1038/s41416-019-0724-y

Ejemplares similares